Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Weiqida Pharmaceutical Co., Ltd. (hereinafter referred to as Sinopharm Weiqida), a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration to approve injectable ceftriaxone to pass the consistent evaluation of generic drug quality and efficacy.

According to reports, ceftriaxone is a long-term, broad-spectrum third-generation cephalosporin antibiotic. Clinically, it is commonly used for infections caused by pathogens sensitive to this product, such as: sepsis; meningitis; disseminated Lyme disease (early and advanced); abdominal infections (peritonitis, biliary tract and gastrointestinal infections); bone, joint, soft tissue, skin and wound infections; infections in patients with poor immune mechanisms; kidney and urinary tract infections; respiratory infections, especially pneumonia, ENT infections; including reproductive system infections; gonorrhea; prevention of infection before surgery, etc.

According to the announcement, Sinopharm Wichida's adoption of ceftriaxone for injections will facilitate future market expansion and sales of this product. The above matters will not have a significant impact on the company's current business performance.